This is a working overview of hGH fragment, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-11-07. Anything still debated is marked as such rather than presented as settled.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
is the diffusion coefficient of the analyte. According to this equation, the efficiency of separation is only limited by diffusion and is proportional to the strength of the electric field, although practical considerations limit the strength of the electric field to several hundred volts per centimeter. Application of very high potentials (>20-30 kV) may lead to arcing or breakdown of the capillary. Further, application of strong electric fields leads to resistive heating (Joule heating) of the buffer in the capillary. At sufficiently high field strengths, this heating is strong enough that radial temperature gradients can develop within the capillary. Since electrophoretic mobility of ions is generally temperature-dependent (due to both temperature-dependent ionization and solvent viscosity effects), a non-uniform temperature profile results in variation of electrophoretic mobility across the capillary, and a loss of resolution. The onset of significant Joule heating can be determined by constructing an "Ohm's Law plot", wherein the current through the capillary is measured as a function of applied potential. At low fields, the current is proportional to the applied potential (Ohm's Law), whereas at higher fields the current deviates from the straight line as heating results in decreased resistance of the buffer. The best resolution is typically obtained at the maximum field strength for which Joule heating is insignificant (i.e. near the boundary between the linear and nonlinear regimes of the Ohm's Law plot).
Because of that, the same predictive effect is expected for the HLB index of sucrose ester, although this index has not be built on the basis of an experimental scale, but on the basis of a calculation. By using the same notion of HLB for different categories of surfactants, it is also expected that this tool would be predictive for comparing surfactants belonging to different families, e.g. PEO surfactants and sucrose esters emulsifiers. It is not the case as long as experiments have not brought evidence that correspondences are possible between the scales applied to different surfactants families. Otherwise, it brings confusion. Non-ionic carbohydrate surfactants have a very different chemical structure and different physicochemical properties compared to polyethylene oxide surfactants family. It is the case notably for their emulsifying properties, for their sensitivity to temperature and their interaction with water through hydrogen bonding. Hence, by using the same calculated HLB scale for sucrose fatty acid esters and for polyethylene surfactants, instead of an experimental HLB scale, it is very likely that this scale will not predict properly the properties of sucrose esters. For the same reason, comparison of sucrose esters with non-ionic carbohydrate based surfactants such as Tween series is also uncertain, because the latter are grafted with polyethylene oxide chains that make them behave as PEO surfactants rather than carbohydrate surfactants.
== History == Although the applications of pharmacometabolomics to personalized medicine are largely only being realized now, the study of an individual's metabolism has been used to treat disease since the Middle Ages. Early physicians employed a primitive form of metabolomic analysis by smelling, tasting and looking at urine to diagnose disease. Obviously the measurement techniques needed to look at specific metabolites were unavailable at that time, but such technologies have evolved dramatically over the last decade to develop precise, high-throughput devices, as well as the accompanying data analysis software to analyze output. Currently, sample purification processes, such as liquid or gas chromatography, are coupled with either mass spectrometry (MS)-based or nuclear magnetic resonance (NMR)-based analytical methods to characterize the metabolite profiles of individual patients. Continually advancing informatics tools allow for the identification, quantification and classification of metabolites to determine which pathways may influence certain pharmaceutical interventions. One of the earliest studies discussing the principle and applications of pharmacometabolomics was conducted in an animal model to look at the metabolism of paracetamol and liver damage. NMR spectroscopy was used to analyze the urinary metabolic profiles of rats pre- and post-treatment with paracetamol. The analysis revealed a certain metabolic profile associated with increased liver damage following paracetamol treatment.
i.e. the baseline vaccination rate should be greater than the "mandatory vaccination" threshold, which, in case of exemption, cannot hold. Thus, "rational" exemption might be myopic since it is based only on the current low incidence due to high vaccine coverage, instead taking into account future resurgence of infection due to coverage decline.
Sources: en.wikipedia.org
In 1999, Yates’ group [11] loaded strong-cation exchange (SCX) and reversed phase liquid chromatography (RPLC) stationary phases sequentially into a capillary column coupled with tandem mass spectrometry (MS/MS) in the analysis of peptides, which became one of the most efficient technique in proteomics afterwards.
Each facility operating an x-ray unit shall have sufficient personnel with appropriate expertise. The person responsible for radiation protection or one or more Radiation Safety Officers shall have appropriate qualifications, which shall be regularly updated. X-ray examinations may be technically performed by any other staff member of a medical or dental practice if they are under the direct supervision and responsibility of the person responsible and if they have knowledge of radiation protection. This knowledge of radiation protection has been required since the amendment of the X-ray Ordinance in 1987; medical and dental assistants (then called medical assistants or dental assistants) received this additional training in 1990. The regulations for the specialty of radiology were tightened by the Radiation Protection Act, which came into force on October 1, 2017. The handling of radioactive substances and ionizing radiation (if not covered by the X-ray Ordinance) is regulated by the Radiation Protection Ordinance (StrlSchV). Section 30 StrlSchV § 30 StrlSchV (in German) defines the "Required expertise and knowledge in radiation protection".
One femtomole is exactly 602214076 molecules; attomole and smaller quantities do not correspond to a whole number of entities. The yoctomole, equal to around 0.6 of an individual molecule, did make appearances in scientific journals in the year the yocto- prefix was officially implemented.
Sources: en.wikipedia.org
When used for analysis of mixtures, the eluant is usually collected in fractions of 1–5 ml which can be further analyzed. When used for protein purification there may be only two collection containers: one for the purified product and one for waste.
Scintigraphy is a nuclear medicine procedure in which low-level radioactive substances are injected into the patient for diagnostic purposes. These include bone scintigraphy, thyroid scintigraphy, octreotide scintigraphy, and, as a further development of the procedure, single photon emission computed tomography (SPECT). For example, 201Tl thallium(I) chloride, technetium compounds (99mTc tracer, 99mtechnetium tetrofosmin), PET tracers (with radiation exposure of 1100 MBq each with 15O-water, 555 MBq with 13N ammonia, or 1850 MBq with 82Rb rubidium chloride) are used in myocardial scintigraphy to diagnose blood flow conditions and function of the heart muscle (myocardium). The examination with 74 MBq 201Thallium Chloride causes a radiation exposure of about 16 mSv (effective dose equivalent), the examination with 740 MBq 99mTechnetium-MIBI about 7 mSv. Metastable 99mTc is by far the most important nuclide used as a tracer in scintigraphy because of its short half-life, the 140 keV gamma radiation it emits, and its ability to bind to many active biomolecules. Most of this radiation is excreted after the examination. The remaining 99mTc decays rapidly to 99Tc with a half-life of 6 hours. This has a long half-life of 212,000 years and, because of the relatively weak beta radiation released during its decay, contributes only a small amount of additional radiation exposure over the remaining lifetime. In the United States alone, approximately seven million individual doses of 99mTc are administered each year for diagnostic purposes.
== Biosynthesis == The peptidoglycan monomers are synthesized in the cytosol and are then attached to a membrane carrier bactoprenol. Bactoprenol transports peptidoglycan monomers across the cell membrane where they are inserted into the existing peptidoglycan.
Such an inflexible dosing regime limits the utility benzodiazepines offer in practice; e.g. lorazepam and alprazolam can be used as needed for situational anxiety in which continuous use is unnecessary or excessive, while clonazepam can be titrated to response when continuous relief is indicated, up to a maximum of 4 mg a day, four times greater than the dose used in comparison with etifoxine over the 24 week duration of the trial. In general, they offer a degree of personalization that is not possible with etifoxine. Indeed, better evidence is required before etifoxine can be said to replace benzodiazepines in practice, especially considering the trials above were relatively small in size, along with the high attrition rates and lack of personalization of the benzodiazepines used. The usual dosage of etifoxine (as the hydrochloride salt) is 150 to 200 mg per day in divided doses of 50 to 100 mg two to three times per day (e.g., 50 mg–50 mg–100 mg). It is taken for a few days to a few weeks, but no longer than 12 weeks.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.